FIELD: medicine.
SUBSTANCE: present group of inventions relates to neurology and psychiatry, and concerns the treatment of neurogenetic syndrome associated with a pervasive development disorder. Method comprises administering a composition containing amino acids, a compulsory part of which is histidine. Composition has a weight-to-weight ratio [leu + ile + val]:[his + lys + thr + trp] of less than 1.0.
EFFECT: such quantitative ratio of amino acids in the composition provides effective treatment of pervasive development disorders without further administration of other drugs.
47 cl, 2 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF GLP-1 MOLECULES INTRODUCTION | 2003 |
|
RU2332229C2 |
| ANTIBODIES DIRECTED AGAINST THE INTERLEUKIN 36 (IL-36R) RECEPTOR | 2016 |
|
RU2745898C2 |
| ANTIBODY AGAINST MUC1 | 2019 |
|
RU2792347C2 |
| MUTANT OF PHOSPHOLIPASE WITH HIGH ENZYMATIC ACTIVITY | 2019 |
|
RU2818353C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| POLYPEPTIDE HAVING PHOSPHOLIPASE C ACTIVITY, AND USE THEREOF | 2019 |
|
RU2819269C2 |
| PHENYLALANINE-FREE PROTEIN FOR TREATMENT OF PKU | 2017 |
|
RU2764796C2 |
| BISPECIFIC ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND METHOD FOR PRODUCTION THEREOF | 2021 |
|
RU2818312C1 |
| ANTI-MUC1 DRUG CONJUGATE | 2019 |
|
RU2804703C2 |
| VERSIONS OF FACTOR N-BINDING PROTEIN AND METHODS OF USE THEREOF | 2015 |
|
RU2714248C2 |
